Balanced news tone
News Sentiment
IMU sentiment intelligence
Imugene Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
23 relevant articles
Price is moving more forcefully than the current news tone suggests.
93/100 classification confidence.
directly relevant articles
high-authority source matches
-22.2% over one week, +15.4% over four weeks, trend inactive, and below fair value.
Imugene (ASX:IMU) Shares Slide as Investors Weigh the Next Stage of Its Cancer-Immunotherapy Strategy
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
93/100 classification
One-week reaction
-22.2%
Price reacting lower
Trend fit
Trend inactive
15.4% over four weeks
Fair value
-92.7%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
3
Neutral
20
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Kalkine
Direct company coverage
Imugene (ASX:IMU) Shares Slide as Investors Weigh the Next Stage of Its Cancer-Immunotherapy Strategy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 08:16
- Source
- Kalkine
Kalkine
Direct company coverage
Imugene Limited Announces Quotation of 73.7 Million New Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 07:49
- Source
- Kalkine
The Globe and Mail
Direct company coverage
Imugene Updates Director Equity Holdings for Jakob Dupont
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Jul 2026 07:14
- Source
- The Globe and Mail
Kalkine
Direct company coverage
Why Did Imugene (ASX: IMU) Plunge More Than 22% Today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 07 Jul 2026 13:25
- Source
- Kalkine
Kalkine
Direct company coverage
Clinical Trial Progress Sparks Fresh Interest in Imugene (ASX: IMU) Shares
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 07:00
- Source
- Kalkine
Kalkine
Direct company coverage
Technical Analysis on One ASX -Listed Pharmaceuticals, Biotechnology & Life Sciences Stock – IMU
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 07:00
- Source
- Kalkine
grafa.com
Direct company coverage
Imugene reports first complete trial patient response
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 04:05
- Source
- grafa.com
Kalkine
Direct company coverage
Imugene (ASX:IMU): : Is This Biotech About To Surprise The Market?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 07:00
- Source
- Kalkine
Kalkine
Direct company coverage
Imugene (ASX:IMU): Biotech Stock Rockets as FDA Fast Track News Ignites Investor Excitement
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 07:00
- Source
- Kalkine
Kalkine
Direct company coverage
Imugene (ASX:IMU) Shares Rally as FDA Grants Special Status to Lead Cancer Therapy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jun 2026 07:00
- Source
- Kalkine
Kalkine
Direct company coverage
Imugene (ASX:IMU) Progresses Blood Cancer Program With New Patient Dosing Milestone
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2026 07:00
- Source
- Kalkine
grafa.com
Direct company coverage
ASX-listed Imugene doses first azer-cel combination patient
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 May 2026 07:00
- Source
- grafa.com
Proactive financial news
Direct company coverage
Imugene strengthens board with biotech and pharma appointments
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- Proactive financial news
Kalkine
Direct company coverage
What’s Fuelling Imugene’s (ASX: IMU) 20% Rally on ASX Today?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 May 2026 07:00
- Source
- Kalkine
Proactive financial news
Direct company coverage
Imugene flags strong azer-cel response rates and ASCO milestone in March quarter update
- Tone
- Positive 66/100
- Event
- Earnings
- Published
- 30 Apr 2026 07:00
- Source
- Proactive financial news
Kalkine Media
Direct company coverage
ASX All Ordinaries Update: Imugene (ASX:IMU) Biotech Milestone Impact?
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Apr 2026 07:00
- Source
- Kalkine Media
Kalkine
Direct company coverage
Imugene (ASX:IMU) Announces 35M Share Placement, Shares in Focus
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Mar 2026 07:00
- Source
- Kalkine
BiotechDispatch
Direct company coverage
Imugene launches $20 million capital raise to fund expansion of Azer Cel trials
- Tone
- Positive 82/100
- Event
- Market update
- Published
- 12 Mar 2026 07:00
- Source
- BiotechDispatch
Kalkine
Direct company coverage
Imugene (ASX:IMU) Shares Drop 17.39% Despite Azer-cel CAR-T Therapy Progress
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Mar 2026 07:00
- Source
- Kalkine
The Motley Fool Australia
Direct company coverage
Why Artrya, Clinuvel, Imugene, and Pilbara Minerals shares are storming higher today
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 08 Dec 2025 08:00
- Source
- The Motley Fool Australia
Proactive financial news
Direct company coverage
Imugene's CAR-T therapy hits 82% response rate
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Dec 2025 08:00
- Source
- Proactive financial news
smallcaps.com.au
Direct company coverage
Insights: Imugene Ltd (ASX:IMU)
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Oct 2025 13:06
- Source
- smallcaps.com.au
Stockhead
Direct company coverage
Here’s what biotech Imugene needs to do before it can become a multibagger again
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 Aug 2022 07:00
- Source
- Stockhead